Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection with ex vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells
Sponsor: |
CUMC |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS9079 |
U.S. Govt. ID: |
NCT05183490 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to test whether giving an experimental cell product can treat viral infection in patients who have conditions that cause the poor function of their immune system. The patients with infections caused by viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), BK and JC polyomaviruses (PyVs) virus may participate in this study. The cell product is called rapidly generated virus-specific T cells (R-MVST). R-MVST cells will be manufactured in our laboratory at Columbia University Irving Medical Center. This cell product has not been approved by the Food and Drug Administration (FDA).
Investigator
Pawel Muranski, MD
Are you over the age of 18? |
Yes |
No |
Have you been diagnosed with a viral infection? |
Yes |
No |
Have you been treated with a steroid, such as prednisone or an equivalent? |
Yes |
No |